caffeic acid phenethyl ester has been researched along with entacapone in 2 studies
Studies (caffeic acid phenethyl ester) | Trials (caffeic acid phenethyl ester) | Recent Studies (post-2010) (caffeic acid phenethyl ester) | Studies (entacapone) | Trials (entacapone) | Recent Studies (post-2010) (entacapone) |
---|---|---|---|---|---|
840 | 1 | 469 | 503 | 112 | 173 |
Protein | Taxonomy | caffeic acid phenethyl ester (IC50) | entacapone (IC50) |
---|---|---|---|
Multidrug resistance-associated protein 4 | Homo sapiens (human) | 6.8 | |
Catechol O-methyltransferase | Homo sapiens (human) | 0.223 | |
Catechol O-methyltransferase | Rattus norvegicus (Norway rat) | 1.275 | |
Adenosine receptor A2a | Homo sapiens (human) | 2.32 | |
Alpha-ketoglutarate-dependent dioxygenase FTO | Homo sapiens (human) | 3 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Borges, F; Garrido, J; Martínez, A; Martínez-González, L; Mohamed, T; Pérez, DI; Rao, PP; Remião, F; Serrão, P; Shakeri, A; Silva, T; Soares-da-Silva, P; Uriarte, E; Valente, MJ | 1 |
Borges, F; Mohamed, T; Rao, PPN; Remião, F; Shakeri, A; Silva, T; Soares da Silva, P | 1 |
2 other study(ies) available for caffeic acid phenethyl ester and entacapone
Article | Year |
---|---|
Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity.
Topics: Animals; Benzophenones; Blood-Brain Barrier; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Cell Survival; Dose-Response Relationship, Drug; Hepatocytes; Male; Models, Molecular; Molecular Structure; Nitriles; Nitrophenols; Rats; Rats, Wistar; Structure-Activity Relationship; Tolcapone | 2016 |
Repurposing nitrocatechols: 5-Nitro-α-cyanocarboxamide derivatives of caffeic acid and caffeic acid phenethyl ester effectively inhibit aggregation of tau-derived hexapeptide AcPHF6.
Topics: Caffeic Acids; Catechols; Chelating Agents; Copper; Drug Design; Nitro Compounds; Peptides; Phenylethyl Alcohol; Polyphenols; Protein Aggregation, Pathological; Small Molecule Libraries; tau Proteins; Tauopathies | 2019 |